Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html
Thursday, May 24, 2018
FDA Approves Novel Preventive Treatment for Migraine
And since migraine with aura increases risk of stroke your doctor should be up-to-date on this intervention. They seem to have totally missed testing migraine with aura, that data point should have been included by the senior researcher.
ROCKVILLE, Md -- May 18, 2018 -- The US Food and Drug Administration (FDA) has approved erenumab-aooe (Aimovig) for the preventive treatment of migraine in adults.
The treatment is given by once-monthly self-injections. Erenumab-aooe is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
“[Erenumab-aooe] provides patients with a novel option for reducing the number of days with migraine,” said Eric Bastings, MD, FDA’s Center for Drug Evaluation and Research, Rockville, Maryland. “We need new treatments for this painful and often debilitating condition.”
The effectiveness of erenumab-aooe for the preventive treatment of migraine was evaluated in 3 clinical trials. The first study included 955 participants with a history of episodic migraine and compared erenumab-aooe with placebo.
Over the course of s6 months, erenumab-aooe -treated patients experienced, on average, 1 to 2 fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared erenumab-aooe with placebo.
Over the course of 3 months, erenumab-aooe -treated patients experienced, on average, 1 fewer migraine days per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared erenumab-aooe with placebo. In that study, over the course of 3 months, patients treated with erenumab-aooe experienced, on average, 2.5 fewer monthly migraine days than those receiving placebo.
The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.
SOURCE: US Food and Drug Administration